MBOT

Microbot Medical Inc. (MBOT) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Microbot Medical Inc. is a pre-commercial, clinical-stage medical device company focused on developing the LIBERTY® Endovascular Robotic Surgical System, a fully disposable robotic system for endovascular procedures. The company operates as a single segment and has not yet generated revenue from product sales. Operations are primarily based in Israel, with significant exposure to regional geopolitical risks.

Key Financial Metrics

Material Changes vs. Prior Period

• Capital Raise & Liquidity: The company significantly strengthened its balance sheet. Total assets increased from $6.03 million (Dec 31, 2024) to $33.13 million (June 30, 2025), driven by a surge in marketable securities from $2.36 million to $28.59 million following multiple registered direct offerings and warrant exercises in early 2025.
• Expense Growth: Net loss for the six months ended June 30, 2025, increased by $1.26 million compared to the same period in 2024. This was primarily due to increased Research and Development (R&D) costs (up $0.98 million) and General and Administrative (G&A) expenses (up $0.87 million), attributed to higher payroll, bonuses, and outsourcing costs for the LIBERTY system.
• Share Count: Outstanding common shares increased from approximately 19.4 million (Dec 31, 2024) to 37.96 million (June 30, 2025) due to equity issuances and warrant exercises.
• Other Income: The company recognized $0.32 million in other income during the six months ended June 30, 2025, resulting from a legal judgment in the "Mona litigation," compared to zero in the prior year period.

Outlook, Risks, and Management Commentary

• Regulatory Milestones: The company submitted a 510(k) premarket notification to the FDA in December 2024 and anticipates marketing clearance in Q3 2025. CE Mark approval is targeted for the second half of 2026.
• Liquidity Runway: Management believes current funds (approx. $32.7 million) are sufficient to fund operations for more than 12 months from the filing date.
• Geopolitical Risk: The company's R&D is based in Israel. While no material adverse effects have been reported to date, ongoing military operations pose risks to supply chains, subcontractor availability, and flight logistics. The company has no specific contingency plans for escalation.
• Future Capital Needs: The company expects to continue incurring losses and will require additional capital for commercialization. Future funding may come from equity/debt issuances or government grants (e.g., Israeli Innovation Authority).
• Subsequent Events: Between July 1 and August 8, 2025, the company raised an additional ~$13.3 million from the exercise of preferred investment options.

Investor Verification Checklist

• FDA Clearance Timeline: Verify the status of the 510(k) submission and the likelihood of Q3 2025 clearance, as commercialization depends entirely on this milestone.
• Geopolitical Exposure: Assess the specific impact of the Israel-Hamas conflict on the company's ability to manufacture devices and ship them to clinical sites.
• Dilution Risk: Review the terms of outstanding Series G, H, and I preferred investment options (over 27 million shares underlying) and the potential for further dilution upon exercise.
• Burn Rate: Monitor the quarterly cash burn rate against the $32.7 million liquidity position to confirm the 12-month runway estimate.
• Government Grants: Confirm the status of the new $0.63 million grant from the Israeli Innovation Authority approved in July 2025 and any associated royalty obligations.